筛查和鉴定神经胶质瘤中的两个关键生物标志物：LMNB1 和 DLGAP5。
Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas.
机构信息
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
出版信息
Biosci Rep. 2021 May 28;41(5). doi: 10.1042/BSR20210231.
Glioma is the most common primary cancer in the central nervous system. Despite advances in surgery, radiotherapy and chemotherapy over the past decades, the prognosis of glioblastoma patients remains poor. We aim to identify robust gene signatures to better understand the complex molecular mechanisms and to discover potential novel molecular biomarkers for glioma. By exploring GSE16011, GSE4290 and GSE50161 data in Gene Expression Omnibus (GEO) database, we screened out 380 differentially expressed genes between non-tumor and glioma tissues, and further selected 30 hub genes through the Molecular Complex Detection (MCODE) plug-in in Cytoscape. In addition, LMNB1 and DLGAP5 were selected for further analyses due to their high expression in gliomas and were verified by using our cohort. Our study confirmed that LMNB1 and DLGAP5 were up-regulated in gliomas, and patients with high expression of LMNB1 or DLGAP5 had poor survival rate. Furthermore, silence of LMNB1 and DLGAP5 inhibited the proliferation of glioma cells. Together, LMNB1 and DLGAP5 were two potentially novel molecular biomarkers for diagnosis and prognosis of glioma.
神经胶质瘤是中枢神经系统最常见的原发性癌症。尽管在过去几十年中手术、放疗和化疗取得了进展，但胶质母细胞瘤患者的预后仍然很差。我们旨在确定稳健的基因特征，以更好地了解复杂的分子机制，并发现潜在的新的神经胶质瘤分子生物标志物。通过探索基因表达综合数据库（GEO）中的 GSE16011、GSE4290 和 GSE50161 数据，我们筛选出非肿瘤组织和神经胶质瘤组织之间的 380 个差异表达基因，并通过 Cytoscape 中的分子复合物检测（MCODE）插件进一步选择了 30 个枢纽基因。此外，由于 LMNB1 和 DLGAP5 在神经胶质瘤中高表达，因此选择它们进行进一步分析，并通过我们的队列进行验证。我们的研究证实，LMNB1 和 DLGAP5 在神经胶质瘤中上调，高表达 LMNB1 或 DLGAP5 的患者生存率较低。此外，沉默 LMNB1 和 DLGAP5 抑制了神经胶质瘤细胞的增殖。总之，LMNB1 和 DLGAP5 是诊断和预测神经胶质瘤的两个潜在的新的分子生物标志物。
Zotero 插件